^
Association details:
| Biomarker: | TGFBR2 E269* |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
Published date:
10/30/2020
Excerpt:
...mutation status of TGFBR2, RHOA, and PREX2 influenced the PFS of immunotherapy...TGFBR2 p.P525L, p.P129Afs*3, p.E269* mutations had been identified and the median PFS of patients with TGFBR2wt and TGFBR2mt were 5.0 months (95%CI, 2.5–7.4 months) and 1.6 months (95%CI, 1.4–1.8 months; p < 0.001), respectively.
DOI:
10.1186/s12943-020-01274-7
